BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37481552)

  • 1. Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer.
    García-Ortiz MV; Cano-Ramírez P; Toledano-Fonseca M; Cano MT; Inga-Saavedra E; Rodríguez-Alonso RM; Guil-Luna S; Gómez-España MA; Rodríguez-Ariza A; Aranda E
    Clin Epigenetics; 2023 Jul; 15(1):118. PubMed ID: 37481552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
    Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
    Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
    PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
    Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
    JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
    Ben-Ami R; Wang QL; Zhang J; Supplee JG; Fahrmann JF; Lehmann-Werman R; Brais LK; Nowak J; Yuan C; Loftus M; Babic A; Irajizad E; Davidi T; Zick A; Hubert A; Neiman D; Piyanzin S; Gal-Rosenberg O; Horn A; Shemer R; Glaser B; Boos N; Jajoo K; Lee L; Clancy TE; Rubinson DA; Ng K; Chabot JA; Kastrinos F; Kluger M; Aguirre AJ; Jänne PA; Bardeesy N; Stanger B; O'Hara MH; Till J; Maitra A; Carpenter EL; Bullock AJ; Genkinger J; Hanash SM; Paweletz CP; Dor Y; Wolpin BM
    Gut; 2024 Mar; 73(4):639-648. PubMed ID: 38123998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer.
    Toledano-Fonseca M; Cano MT; Inga E; Rodríguez-Alonso R; Gómez-España MA; Guil-Luna S; Mena-Osuna R; de la Haba-Rodríguez JR; Rodríguez-Ariza A; Aranda E
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of tumor suppressor genes methylation in circulating tumor DNA of patients with pancreatic cancer.
    Xin W; Tu S; Yi S; Xiong Y; Fang K; Sun G; Xiao W
    Gene; 2024 Mar; 897():148078. PubMed ID: 38097094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
    Brancaccio M; Natale F; Falco G; Angrisano T
    Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31877923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
    Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
    Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Multiplex Detection of
    Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
    Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
    Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
    Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
    Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer.
    Peter MR; Bilenky M; Shi Y; Pu J; Kamdar S; Hansen AR; Fleshner NE; Sridhar SS; Joshua AM; Hirst M; Xu W; Bapat B
    Epigenomics; 2022 Jul; 14(13):811-822. PubMed ID: 35818933
    [No Abstract]   [Full Text] [Related]  

  • 16. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta-analysis.
    Huang W; Xue L; Xu H; Kong Z; Xu J; Zhao H; Nie Y
    Int J Clin Pract; 2021 Sep; 75(9):e14443. PubMed ID: 34105851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.
    Gall TMH; Belete S; Khanderia E; Frampton AE; Jiao LR
    Am J Pathol; 2019 Jan; 189(1):71-81. PubMed ID: 30558725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.
    Deger T; Boers RG; de Weerd V; Angus L; van der Put MMJ; Boers JB; Azmani Z; van IJcken WFJ; Grünhagen DJ; van Dessel LF; Lolkema MPJK; Verhoef C; Sleijfer S; Martens JWM; Gribnau J; Wilting SM
    Clin Epigenetics; 2021 Oct; 13(1):196. PubMed ID: 34670587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.